|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Gemfibrozil#Drug Interactions]] |
| {{Gemfibrozil}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| ===HMG-CoA Reductase Inhibitors===
| |
| | |
| The concomitant administration of LOPID with [[simvastatin]] is contraindicated (see CONTRAINDICATIONS and WARNINGS). The risk of [[myopathy]] and [[rhabdomyolysis]] is increased with combined gemfibrozil and [[HMG-CoA]] reductase inhibitor therapy. [[Myopathy]] or [[rhabdomyolysis]] with or without acute [[renal failure ]]have been reported as early as three weeks after initiation of combined therapy or after several months (see WARNINGS). There is no assurance that periodic monitoring of creatine kinase will prevent the occurrence of severe [[myopathy]] and kidney damage.
| |
| | |
| ===Anticoagulants===
| |
| | |
| '''CAUTION SHOULD BE EXERCISED WHEN ANTI-COAGULANTS ARE GIVEN IN CONJUNCTION WITH LOPID. THE DOSAGE OF THE ANTICOAGULANT SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN LEVEL HAS STABILIZED'''.
| |
| | |
| ===Repaglinide===
| |
| | |
| In healthy volunteers, co-administration with gemfibrozil (600 mg twice daily for 3 days) resulted in an 8.1-fold (range 5.5- to 15.0- fold) higher [[repaglinide]]AUC and a 28.6-fold (range 18.5- to 80.1-fold) higher [[repaglinide]]plasma concentration 7 hours after the dose. In the same study, gemfibrozil (600 mg twice daily for 3 days) + [[itraconazole]] (200 mg in the morning and 100 mg in the evening at Day 1, then 100 mg twice daily at Day 2–3) resulted in a 19.4- (range 12.9- to 24.7-fold) higher [[repaglinide]]AUC and a 70.4-fold (range 42.9- to 119.2-fold) higher [[repaglinide]]plasma concentration 7 hours after the dose. In addition, gemfibrozil alone or gemfibrozil + [[itraconazole]] prolonged the [[hypoglycemic]] effects of [[repaglinide]]. Co-administration of gemfibrozil and [[repaglinide]]increases the risk of severe [[hypoglycemia]] and is contraindicated (see CONTRAINDICATIONS).
| |
| | |
| ===Bile Acid-Binding Resins===
| |
| | |
| Gemfibrozil AUC was reduced by 30% when gemfibrozil was given (600 mg) simultaneously with resin-granule drugs such as colestipol (5 g). Administration of the drugs two hours or more apart is recommended because gemfibrozil exposure was not significantly affected when it was administered two hours apart from colestipol.
| |
| | |
| ===Colchicine===
| |
| [[Myopathy]], including [[rhabdomyolysis]], has been reported with chronic administration of [[colchicine]] at therapeutic doses. Concomitant use of LOPID may potentiate the development of myopathy. Patients with [[renal dysfunction]] and elderly patients are at increased risk. Caution should be exercised when prescribing LOPID with colchicine, especially in elderly patients or patients with [[renal dysfunction]]<ref>{{Cite web | last = | first = | title = DailyMed: Search | url = http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=+Lopid&x=11&y=10 | publisher = | date = | accessdate = 13 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
|
| |
|
| | [[Category: Cardiovascular Drugs]] |
| | [[Category: Drug]] |
| [[Category:Fibrates]] | | [[Category:Fibrates]] |
| [[Category:Phenol ethers]]
| |
| [[Category:Cardiovascular Drug]]
| |
| [[Category:Drug]]
| |